Startup profile · funding coverage
Genesis Molecular AI
AI-first drug discovery company using generative models for small-molecule design.
Stage
series b
Status
private
Coverage
full
Why Genesis Molecular AI is interesting
Genesis Molecular AI raised $200M to scale its GEMS platform; a16z led the seed and co-led Series B with Menlo Ventures. Rebranded from Genesis Therapeutics.
Key facts
- Series B (2023): $200M co-led by a16z Bio + Health (/fund/andreessen-horowitz) with Menlo Ventures (/fund/menlo-ventures) (BusinessWire)
- Rebranded from Genesis Therapeutics to Genesis Molecular AI; GEMS platform for small-molecule drug discovery
- Pharma partnerships include Genentech (2020) and Eli Lilly (2022)
Investors in our directory
Funds linked from Genesis Molecular AI's profile — open a fund page for stage focus and related deal articles.
Industries
AI & Machine Learning Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Genesis Molecular AI's financing or category context.
FAQs about Genesis Molecular AI
Funding context and why this company shows up in venture coverage.
Genesis Molecular AI builds foundation models for drug discovery. Its GEMS (Genesis Exploration of Molecular Space) platform uses generative AI and physics-based simulation to design small-molecule drug candidates for difficult protein targets.
Genesis Molecular AI's $200M Series B (2023) was co-led by Andreessen Horowitz (/fund/andreessen-horowitz) Bio + Health and Menlo Ventures (/fund/menlo-ventures). a16z also led the company's seed round.
Genesis Molecular AI is at Series B based on its August 2023 $200M round.
Genesis combines generative diffusion models with physics-based chemistry — targeting data-poor and previously undruggable protein targets. Pharma partners include Genentech and Eli Lilly.
Yes. Genesis Therapeutics rebranded to Genesis Molecular AI to reflect its focus on foundation models for molecular AI. Both entries in this directory refer to the same company.
Last updated: 2026-07-24